Clinical pathway for transcatheter mitral valve edge-to-edge repair in China (abbreviated version 2022)
- VernacularTitle:中国经导管二尖瓣缘对缘修复术临床路径（2022精简版）
- Author:
Yongjian WU
1
;
Yixian LIN
2
;
Daxin ZHOU
3
;
Guangyuan SONG
4
Author Information
1. National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China
2. Asian Heart Disease Center, Canossa Hospital, Hong Kong, P. R. China
3. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China
4. Department of Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, P. R. China
- Collective Name:Structural Cardiology Committee of Cardiovascular Physicians Branch, Chinese Medical Doctor Association, Asia Pacific Structural Heart Disease Club
- Publication Type:Journal Article
- Keywords:
Transcatheter mitral valve edge-to-edge repair;
imaging;
procedure;
perioperative management;
rehabilitation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(03):333-343
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter mitral valve edge-to-edge repair (TEER) has become an important treatment opinion for patients with severe mitral regurgitation (MR) at high risk for surgery. The devices and procedural techniques of TEER are complex and require excellent team cooperation. However, there is still a lack of standardized clinical pathways in China. Based on the latest evidence, the expert group wrote this clinical pathway to guide and optimize TEER therapy in clinical practice. It demonstrates the following key issues of clinical concern: (1) TEER team building; (2) preoperative clinical evaluation of TEER patients; (3) imaging assessment before TEER procedure; (4) standardized procedures for TEER; (5) TEER for complex MR; (6) the standard process of perioperative comprehensive management; and (7) full life-cycle rehabilitation and follow-up. This clinical pathway might be helpful to facilitate the standardized development of TEER therapy and application, and promote the improvement of management and life quality for patients with MR.
